The invention concerns the treatment of cardiac hypertrophy by interferon-gamma (IFN-). Cardiac hypertrophy may result from a variety of diverse pathologic conditions, including myocardial infarction, hypertension, hypertrophic cardiomyopathy, and valvular regurgitation. The treatment extends to all stages of the progression of cardiac hypertrophy, with or without structural damage of the heart muscle, regardless of the underlying cardiac disorder.


< Rapid classification of biological components

< Methods of treating dopamine dysregulation using agents that regulate phosphorylation/dephosphorylation in dopamine signaling

> Methods of treatment with erythropoietin and albumin fusion protein

> Exendins, exendin agonists, and methods for their use

~ 00233